<DOC>
	<DOC>NCT01488877</DOC>
	<brief_summary>PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy</brief_title>
	<detailed_description>This study was terminated on 12-Sep-2012; this decision was made due to poor recruitment and overall business strategy. The study was not terminated for safety reasons nor for lack of efficacy.</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Males and/or Females between 1865 years, inclusive. Body mass index of 18.5 to 45.4 kg/m2 at screening, inclusive. body weight equals or greater than 110 lb. Have type 2 diabetes mellitus. On stable dose of antidiabetic and antihypertensive medication prior to screening. Recent evidence or medical history of unstable concurrent disease. Cardiovascular event within 3 months prior to screening. History of renal transplant. History of hospitalization for acute kidney injury or acute kidney dialysis within 6 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 diabetes mellitus. albuminuria.</keyword>
</DOC>